[1]
|
George, J., Lim, J.S., Jang, S.J., Cun, Y., Ozretic, L., Kong, G., et al. (2015) Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature, 524, 47-53. https://doi.org/10.1038/nature14664
|
[2]
|
Peifer, M., Fernández-Cuesta, L., Sos, M.L., George, J., Seidel, D., Kasper, L.H., et al. (2012) Integrative Genome Analyses Identify Key Somatic Driver Mutations of Small-Cell Lung Cancer. Nature Genetics, 44, 1104-1110. https://doi.org/10.1038/ng.2396
|
[3]
|
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A.V., et al. (2013) Signatures of Mutational Processes in Human Cancer. Nature, 500, 415-421. https://doi.org/10.1038/nature12477
|
[4]
|
Liu, S.V., Reck, M., Mansfield, A.S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M.C., et al. (2021) Updated Overall Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 39, 619-630. https://doi.org/10.1200/JCO.20.01055
|
[5]
|
Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Genesuperfamily, upon Programmed Cell Death. EMBO Journal, 11, 3887-3895. https://doi.org/10.1002/j.1460-2075.1992.tb05481.x
|
[6]
|
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H. and Honjo, T. (1996) Expression of the PD-1 Antigen on the Surface of Stimulated Mouse T and B Lymphocytes. International Immunology, 8, 765-772. https://doi.org/10.1093/intimm/8.5.765
|
[7]
|
Luo, H., Song, G.B., Wang, D., et al. (2022) Combining PD-1 or PD-L1 Inhibitors with Chemotherapy Is a Good Strategy for the Treatment of Extensive Small Cell Lung Cancer: A Retrospective Analysis of Clinical Studies. Frontiers in Immunology, 13, Article ID: 1059557. https://doi.org/10.3389/fimmu.2022.1059557
|
[8]
|
Sabari, J.K., Lok, B.H., Laird, J.H., et al. (2017) Unravelling the Biology of SCLC: Implications for Therapy. Nature Reviews Clinical Oncology, 14, 549-561. https://doi.org/10.1038/nrclinonc.2017.71
|
[9]
|
Dutta, R., Rathor, A., Sharma, H.P., et al. (2023) Mapping the Immune Landscape in Small Cell Lung Cancer by Analysing Expression of Immuno-Modulators in Tissue Biopsies and Paired Blood Samples. Scientific Reports, 13, Article No. 3739. https://doi.org/10.1038/s41598-023-30841-3
|
[10]
|
Zheng, P. and Zhou, Z. (2015) Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. Biomarkers in Cancer, 7, 15-18. https://doi.org/10.4137/BIC.S29325
|
[11]
|
Lesterhuis, W.J., Steer, H. and Lake, R.A. (2011) PD-L2 Is Predominantly Expressed by Th2 Cells. Molecular Immunology, 49, 1-3. https://doi.org/10.1016/j.molimm.2011.09.014
|
[12]
|
Youngnak, P., Kozono, Y., Kozono, H., Iwai, H., Otsuki, N., Jin, H., Omura, K., Yagita, H., Pardoll, D.M., Chen, L., et al. (2003) Differential Binding Properties of B7-H1 and B7-DC to Programmed Death-1. Biochemical and Biophysical Research Communications, 307, 672-677. https://doi.org/10.1016/S0006-291X(03)01257-9
|
[13]
|
Yang, G.H., Sun, H.F., Sun, N.N., et al. (2022) Efficacy and Safety Comparison of PD-1 Inhibitors PD-L1 Inhibitors in Extensive-Stage Small-Cell Lung Cancer: A Retrospective Comparative Cohort Study. Journal of Thoracic Disease, 14, 4925-4937. https://doi.org/10.21037/jtd-22-1682
|
[14]
|
Dou, X.Y., Hua, Y., et al. (2022) Extracellular Vesicles Containing PD-L1 Contribute to CD8+ T-Cell Immune Suppression and Predict Poor Outcomes in Small Cell Lung Cancer. Clinical & Experimental Immunology, 207, 307-317. https://doi.org/10.1093/cei/uxac006
|
[15]
|
Gelsomino, F., Lamberti, G., Parisi, C., et al. (2019) The Evolving Landscape of Immunotherapy in Small-Cell Lung Cancer: A Focus on Predictive Biomarkers. Cancer Treatment Reviews, 79, Article ID: 101887. https://doi.org/10.1016/j.ctrv.2019.08.003
|
[16]
|
Li, H., Xu, Y., Wan, B., Song, Y., Zhan, P., Hu, Y., et al. (2019) The Clinicopathological and Prognostic Significance of PD-L1 Expression Assessed by Immunohistochemistry in Lung Cancer: A Meta-Analysis of 50 Studies with 11,383 Patients. Translational Lung Cancer Research, 8, 429-449. https://doi.org/10.21037/tlcr.2019.08.04
|
[17]
|
Schultheis, A.M., Scheel, A.H., Ozretic, L., George, J., Thomas, R.K., Hagemann, T., et al. (2015) PD-L1 Expression in Small Cell Neuroendocrine Carcinomas. European Journal of Cancer, 51, 421-426. https://doi.org/10.1016/j.ejca.2014.12.006
|
[18]
|
Ishii, H., Azuma, K., Kawahara, A., Yamada, K., Imamura, Y., Tokito, T., et al. (2015) Significance of Programmed Cell Death-Ligand 1 Expression and Its Association with Survival in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology, 10, 426-430. https://doi.org/10.1097/JTO.0000000000000414
|
[19]
|
Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., et al. (2017) PD-L1 Expression in Neuroendocrine Tumors of the Lung. Lung Cancer, 108, 115-120. https://doi.org/10.1016/j.lungcan.2017.03.006
|
[20]
|
Carvajal-Hausdorf, D., Altan, M., Velcheti, V., et al. (2019) Expression and Clinical Significance of PD-L1, B7-H3, B7-H4 and TILs in Human Small Cell Lung Cancer (SCLC). The Journal for ImmunoTherapy of Cancer, 7, Article No. 65. https://doi.org/10.1186/s40425-019-0540-1
|
[21]
|
Ameratunga, M., Asadi, K., Lin, X., Walkiewicz, M., Murone, C., Knight, S., Mitchell, P., Boutros, P. and John, T. (2016) PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLOS ONE, 11, e0153954. https://doi.org/10.1371/journal.pone.0153954
|
[22]
|
Boland, J.M., Kwon, E.D., Harrington, S.M., Wampfler, J.A., Tang, H., Yang, P. and Aubry, M.C. (2013) Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung. Clinical Lung Cancer, 14, 157-163. https://doi.org/10.1016/j.cllc.2012.05.006
|
[23]
|
Casadevall, D., Clavé, S., Taus, á., Hardy-Werbin, M., Rocha, P., Lorenzo, M., Menéndez, S., Salido, M., Albanell, J., Pijuan, L., et al. (2017) Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clinical Lung Cancer, 18, 682-691.e5. https://doi.org/10.1016/j.cllc.2017.04.014
|
[24]
|
Chatterjee, M. (2016) Systematic Evaluation of Pembrolizumab Dosing in Patients with Advanced Non-Small-Cell Lung Cancer. Annals of Oncology, 27, 1291-1298. https://www.medscape.com/medline/abstract/27117531
|
[25]
|
Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. https://doi.org/10.1016/S1470-2045(16)30098-5
|
[26]
|
Ott, P., Felip, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., et al. (2017) Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028. Journal of Thoracic Oncology, 12, S259. https://doi.org/10.1016/j.jtho.2016.11.250
|
[27]
|
Chung, H.C., Lopez-Martin, J.A., Kao, S.C.-H., Miller, W.H., Ros, W., Gao, B., et al. (2018) Phase 2 Study of Pembrolizumab in Advanced Small-Cell Lung Cancer (SCLC): KEYNOTE-158. Journal of Clinical Oncology, 36, Article No. 8506. https://doi.org/10.1200/JCO.2018.36.15_suppl.8506
|
[28]
|
Pulliam, S., Karki, N.R., Khan, J., Jogezai, S., Sultan, S., Muhammad, L., Khan, M., Jamil, N., Waheed, A., et al. (2022) PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies? Clinics and Practice, 12, 653-671. https://doi.org/10.3390/clinpract12050068
|
[29]
|
Kintsler, S., Cassataro, M.A., Drosch, M., Holenya, P., Knuechel, R. and Braunschweig, T. (2019) Expression of Programmed Death Ligand (PD-L1) in Different Tumors. Comparison of Several Current Available Antibody Clones and Antibody Profiling. Annals of Diagnostic Pathology, 41, 24-37. https://doi.org/10.1016/j.anndiagpath.2019.05.005
|
[30]
|
Chung, H.C., Piha-Paul, S.A., Lopez-Martin, J., Schellens, J., Kao, S., Miller, W.H., et al. (2020) Pembrolizumab after Two or More Lines of Previous Therapy in Patients with Recurrent or Metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 Studies. Journal of Thoracic Oncology, 15, 618-627. https://doi.org/10.1016/j.jtho.2019.12.109
|